The National Institute for Health and Clinical Excellence (NICE) approved Toctino (alitretinoin) as a treatment for eczema in July 2009. The Swiss group Basilea’s Toctino has been approved under the NHS for adults with severe hand eczema, with a dermatology life quality index score of 15 or more, who have failed to respond to therapy with topical corticosteroids. The drug, which costs £411.43 for a pack of 30 x 30mg capsules (excluding VAT), is considered a cost-effective use of resources as the cost per QALY is well below the threshold required.
Further reading - A detailed analysis of the UK pharmaceutical market, including some background information on NICE, is available from Espicom: The Pharmaceutical Market: United Kingdom (published June 2009)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment